Pharmaceutical News

RSS

GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

New analyses from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) will be presented at ESC Congress 2015 to be held in London, United Kingdom, from August 29 to September 2, 2015.

20 Aug 2015

Experimental MERS-CoV vaccine shows promise in monkeys and camels

National Institutes of Health scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels.

20 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

Women's contraceptive choices often driven by relationships, sexual activity

Women's contraceptive choices are more often driven by current relationships and sexual activity than by long-term pregnancy intentions, according to Penn State College of Medicine researchers.

19 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA.

19 Aug 2015

Even the Score issues statement on FDA approval of flibanserin for treatment of women with HSDD

Even the Score issued the following statement following today's historic approval by the Food and Drug Administration of flibanserin (Addyi), the first-ever medical treatment option for women's most common sexual dysfunction, known as Hypoactive Sexual Desire Disorder (HSDD).

18 Aug 2015

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co.'s $2.37 billion settlement didn't attract enough claimants to participate in the deal, which said the company would fund the deal after 95% of claimants joined it.

18 Aug 2015

Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan N.V. today confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Abiraterone Acetate Tablets, 250 mg.

18 Aug 2015

Hi-Tech acquires LG Sciences brand of Sports Nutrition and Bodybuilding products

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and LG Sciences, one of the premier Sports Nutrition and Bodybuilding brands in the United States, today announced that Hi-Tech has acquired LG Sciences brand of Sports Nutrition products and Bodybuilding products.

18 Aug 2015

Researchers examine how GABA supplementation enhances planning, controls different actions

People show an enhanced ability of prioritizing planned actions after the ingestion of the food supplement GABA. Psychologists Laura Steenbergen and Lorenza Colzato, with their colleagues at the Leiden Institute of Brain and Cognition and fellow researchers from the Technical University of Dresden, published their findings in Scientific Reports.

18 Aug 2015

New prescription smoking-cessation drug not helping smokers quit

The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a study led by researchers at University of California, San Diego School of Medicine.

18 Aug 2015

Vitamin D supplements may help reduce risk of falls in homebound elderly

Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury. Even if an injury does not occur, the fear of falling can lead to reduced activity and a loss of independence.

18 Aug 2015

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

Boehringer Ingelheim announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto® Respimat® (tiotropium/olodaterol) provides consistent, clinically meaningful improvements in quality of life versus placebo in patients with COPD

17 Aug 2015

Omeros plans to file patent infringement lawsuit against Par

Omeros Corporation today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

17 Aug 2015

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.

17 Aug 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Veloxis Pharmaceuticals A/S, today announced that Envarsus XR was granted Orphan Drug status by the U.S. Food and Drug Administration for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus XR received marketing authorization from the FDA on July 10, 2015.

14 Aug 2015

Risk for endophthalmitis no higher with Avastin, finds study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Their findings are published today in JAMA Ophthalmology.

14 Aug 2015

Pharmaceutical News

GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

Experimental MERS-CoV vaccine shows promise in monkeys and camels

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Women's contraceptive choices often driven by relationships, sexual activity

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Even the Score issues statement on FDA approval of flibanserin for treatment of women with HSDD

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

Mylan sued in connection with ANDA filing for generic version of Zytiga

Hi-Tech acquires LG Sciences brand of Sports Nutrition and Bodybuilding products

Researchers examine how GABA supplementation enhances planning, controls different actions

New prescription smoking-cessation drug not helping smokers quit

Vitamin D supplements may help reduce risk of falls in homebound elderly

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

Omeros plans to file patent infringement lawsuit against Par

NanoViricides speeds up HerpeCide drug development program

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Risk for endophthalmitis no higher with Avastin, finds study

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News